行情

CLRB

CLRB

Cellectar
NASDAQ

实时行情|Nasdaq Last Sale

2.660
+0.040
+1.53%
盘后: 2.640 -0.02 -0.75% 17:52 01/27 EST
开盘
2.620
昨收
2.620
最高
2.750
最低
2.600
成交量
15.59万
成交额
--
52周最高
3.750
52周最低
1.040
市值
2,496.86万
市盈率(TTM)
-1.1254
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CLRB 新闻

  • Roth Capital Assumes Cellectar Biosciences at Buy, Announces $10 Price Target
  • Benzinga.6天前
  • Should You Be Concerned About Cellectar Biosciences, Inc.'s (NASDAQ:CLRB) Historical Volatility?
  • Simply Wall St..01/17 11:41
  • Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020
  • GlobeNewswire.01/09 13:00
  • Humana Tax Repeal, And Other News: The Good, Bad, And Ugly Of Healthcare
  • Seeking Alpha - Article.01/07 14:44

更多

所属板块

制药
-0.42%
制药与医学研究
-0.51%

热门股票

名称
价格
涨跌幅

CLRB 简况

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.
展开

Webull提供Cellectar Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。